Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features

PURPOSE: Cytoreductive therapy is beneficial in patients with essential thrombocythemia (ET) at high risk of thrombosis. However, its value in those lacking high-risk features remains unknown. This open-label, randomized trial compared hydroxycarbamide plus aspirin with aspirin alone in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Godfrey, Anna L., Campbell, Peter J., MacLean, Cathy, Buck, Georgina, Cook, Julia, Temple, Julie, Wilkins, Bridget S., Wheatley, Keith, Nangalia, Jyoti, Grinfeld, Jacob, McMullin, Mary Frances, Forsyth, Cecily, Kiladjian, Jean-Jacques, Green, Anthony R., Harrison, Claire N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2018
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269131/
https://www.ncbi.nlm.nih.gov/pubmed/30153096
http://dx.doi.org/10.1200/JCO.2018.78.8414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269131/
https://www.ncbi.nlm.nih.gov/pubmed/30153096
http://dx.doi.org/10.1200/JCO.2018.78.8414

Ejemplares similares